Breathing life into high potential medicines episode artwork

EPISODE · Jul 14, 2023 · 49 MIN

Breathing life into high potential medicines

from Molecule to Market: Inside the outsourcing space · host Raman Sehgal

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Founder and CEO at Vibe Bio.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Alok, covering:   The personal story that motivated and inspired Alok to create a rare disease platform focused entirely on creating an ecosystem focused on high potential medicines. Lessons from ‘the grind’ of raising over $100m in capital, and why you need a ‘Minimal Viable Investor’ (MVI) The macro impact of Covid-19 in highlighting the importance of medicines - and why this is a time for optimism, innovation and technology in biotech. The catch-22 of inflection points for biotechs and how that impacts access to capital. And whether AI could play a pivotal role. How CDMOs and CROs need to evolve away from just the fee-for-service model to explore longer-term, partnership-led alternatives.   Alok has 15 years of experience as a scientist and 12 as a serial entrepreneur. After completing postdoctoral work at Harvard University with George Whitesides, Alok started two pharma SaaS companies, PreScouter and TetraScience, which employ several hundred people combined and have more than four hundred customers. He also launched and led the life sciences division of Egnyte, a cloud content governance company based in California, and grew the business to a 60-person team and eight-figure run rate.   Alok founded Vibe Bio after his daughter was hospitalized at birth and he learned first-hand that the biggest obstacle to developing treatments isn’t finding potential therapies — it’s funding them. Vibe Bio is helping patients in similar situations overcome that obstacle by scaling the development of treatments for rare disorders sustainably for the first time. He holds a B.S. from Cornell and a Ph.D. from Northwestern, both in Materials Science & Engineering.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Founder and CEO at Vibe Bio.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Alok, covering:   The personal story that motivated and inspired Alok to create a rare disease platform focused entirely on creating an ecosystem focused on high potential medicines. Lessons from ‘the grind’ of raising over $100m in capital, and why you need a ‘Minimal Viable Investor’ (MVI) The macro impact of Covid-19 in highlighting the importance of medicines - and why this is a time for optimism, innovation and technology in biotech. The catch-22 of inflection points for biotechs and how that impacts access to capital. And whether AI could play a pivotal role. How CDMOs and CROs need to evolve away from just the fee-for-service model to explore longer-term, partnership-led alternatives.   Alok has 15 years of experience as a scientist and 12 as a serial entrepreneur. After completing postdoctoral work at Harvard University with George Whitesides, Alok started two pharma SaaS companies, PreScouter and TetraScience, which employ several hundred people combined and have more than four hundred customers. He also launched and led the life sciences division of Egnyte, a cloud content governance company based in California, and grew the business to a 60-person team and eight-figure run rate.   Alok founded Vibe Bio after his daughter was hospitalized at birth and he learned first-hand that the biggest obstacle to developing treatments isn’t finding potential therapies — it’s funding them. Vibe Bio is helping patients in similar situations overcome that obstacle by scaling the development of treatments for rare disorders sustainably for the first time. He holds a B.S. from Cornell and a Ph.D. from Northwestern, both in Materials Science & Engineering.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

NOW PLAYING

Breathing life into high potential medicines

0:00 49:23

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Molecule to Market: Inside the outsourcing space?

This episode is 49 minutes long.

When was this Molecule to Market: Inside the outsourcing space episode published?

This episode was published on July 14, 2023.

What is this episode about?

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Founder and CEO at Vibe Bio.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain...

Can I download this Molecule to Market: Inside the outsourcing space episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!